Bayer : Solid Q4 results - questions about the strategic path remain
>Better-than-expected earnings were driven by strong CS business - This morning, Bayer released better-than-expected FY 2023 earnings, which were predominantly driven by the CropScience division. Group sales are down by 6.1% y-o-y to € 47.6bn (vs our estimate of € 47.2bn and the Vara consensus of € 47.4bn). Pharma sales decreased by 6% to € 18bn (vs € 18.4bn and € 18.3bn). CropScience sales declined 26.6% y-o-y to € 23.3bn (vs € 22.7bn and € 22.9bn). Consumer Health’...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.